http___lysobact.ba_bs_klinicki-dokazi-efikasnosti__1.xml
1.1 1.2 2.1 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1 19.1 20.1 20.2 21.1 22.1 22.2 23.1 24.1 25.1 25.2 26.1 26.2 27.1 28.1 29.1 30.1 31.1 32.1 32.2 33.1 33.2 34.1 35.1 35.2 35.3 36.1 37.1 37.2 37.3 37.4 38.1 39.1 40.1 41.1 42.1 43.1 44.1 45.1 46.1 47.1 48.1 49.1 50.1 51.1 52.1 53.1 54.1 55.1 56.1 57.1
Therapeutic effect of lysozyme in Lysobact® on pathological conditions of the oral mucosa, such as pharyngitis (inflammation of the throat), tonsillitis (inflammation of the tonsils), stomatitis (inflammation of the mucous membranes of the mouth), gingivitis (inflammation of the gums), condition after tonsillectomy…., is studied in several clinical studies with the primary aim of checking anti-inflammatory and antimicrobial activity. Clinical trials have been conducted in a few countries. – Topić B., Čokorilo N., Arifhodžić F.: “Klinička evaluacija preparata Lyso-6®* u tretmanu aftoznog stimatitisa (Clinical evaluation of Lyso-6® * in the treatment of aphthous stimatitis)“ At the Clinic for Oral Diseases of the Faculty of Dentistry in Sarajevo, in a double-blind, placebo-controlled clinical trial, the efficacy and safety of long-term use of Lysobact® oriblet in patients diagnosed with stomatitis aphtosa recurrens was proven. The results of a study involving 60 patients for 8 days were as follows: - the inflammation was cured on the fifth day of therapy - the pain disappears by the fifth day of therapy, which is significantly faster compared to the control placebo group - Healing of aphthous mucosal damage is almost complete on the fifth day, while in the control placebo group mucosal damage is still present at 40% of its baseline size - signs and symptoms caused by reactive lymph node inflammation are significantly milder in patients treated with Lysobact® oriblets compared to the placebo group - Lysobact® effectively reduces the intensity of pain and inflammation, promotes healing of the mucosa at the site of damage and relieves symptoms of inflammation of regional lymph nodes - drug tolerability was outstanding, and no toxic or allergic events were observed * earlier trademark of the Lysobact® – Kapidžić A. et al.: „Otvoreno multicentrično kliničko ispitivanje efikasnosti i sigurnosti primjene lijeka Lysobact® u liječenju i prevenciji postoperativnih komplikacija nakon tonzilektomije“ (Open multicenter clinical trial of the efficacy and safety of Lysobact® in the treatment and prevention of postoperative complications after tonsillectomy) At the Clinic for ENT in Clinical Center of University Sarajevo, in an open, parallel, controlled multicenter study, which included 160 patients aged 16 to 40 years, the efficacy of Lysobact® was examined compared to standard therapy (analgesic and antibiotic). The test results for Lysobact® showed: - significant difference in the formation of fibrin deposits (temporary whitish cover, necessary for easier healing of damage) - greater reduction in pain sensation - faster postoperative wound healing, starting from the second postoperative day - less need for analgesic therapy in patients treated with Lysobact® – Bašić-Đulizarević D., Bajraktarević A., Obradović E: „Evaluacija praktične upotrebe lijeka Lysobact® u periodu 1976 – 2006.“ (Evaluation of the practical use of Lysobact® in the period 1976 – 2006) A meta-analysis of nine prospective clinical trials, reports from the National Center and the Sarajevo Drug Center, a review of the professional literature and many years of experience in the use of the drug shows that Lysobact® has proven excellent efficacy in rapidly healing oral mucosal damage and reducing inflammation, as well as reduction of the subjective pain and burning sensation of the oral mucosa. Lysobact® has proven to be a safe and effective drug with anti-inflammatory and antibacterial, antifungal, antiviral properties with a positive therapeutic effect on bacteria present in dental plaque. – Zabolotnyj DI., Zaricvaja IS.: „Otvorena studija o efikasnosti i podnošljivosti lijeka Lysobact® u liječenju inflamatornih bolesti farniksa“ (Open study on the efficacy and tolerability of Lysobact® in the treatment of inflammatory diseases of the pharynx) An open-label, comparative, parallel study involving 180 patients diagnosed with acute and chronic pharyngitis (pharyngitis) showed that Lysobact® was more effective in relieving symptoms faster than combination therapy with antibiotics and the furacillin solution used for pharyngeal lavage. Lysobact® has shown antibacterial and anti-inflammatory effects and is recommended in patients with acute and chronic pharyngitis. – Zabolotnyj DI., Mironjuk BM.: „Otvorena studija s ciljem procjene podnošljivosti preparata Lysobact® u postoperativnom tretmanu nakon tonzilektomije i kriohirurškom zahvatu na palatalnim tonzilama kod djece“ (Open study to assess the tolerability of Lysobact® in postoperative treatment after tonsillectomy and cryosurgery of the palatal tonsils in children) An open, comparative, parallel study after tonsil surgery, which included 60 children, boys and girls aged 3 to 7 years, showed that Lysobact® is well tolerated and contributes to faster postoperative wound healing. – Andrejčin MA., Borak VP., Išćuk IS., Gospodarska HO. „Efikasnost lijeka Lysobact® u tretmanu grlobolje“ (Efficacy of Lysobact® in the treatment of sore throat) A follow-up study that included 42 patients diagnosed with laryngitis aged 19 to 48 years, in which patients were divided into two groups (one group receiving antibiotic therapy, antiseptic and vitamin and the other group receiving additional Lysobact®). In patients who also received Lysobact®, the test results showed: - faster reduction of fever - faster normalization of laboratory tests - faster disappearance of pus accumulations - faster healing of patients with sore throat Lysobact® has been shown to be a safe and well-tolerated drug. – Burmak i sar. „Kliničko iskustvo sa terapijom preparatom Lysobact® kod djece sa respiratornim virusnim oboljenjem“ (Clinical experience with Lysobact® therapy in children with respiratory viral disease) The results of a follow-up study involving 45 children aged 7 to 14 years with a diagnosis of acute respiratory disease, of whom almost 20% had tonsillitis, showed that improvement in inflammation symptoms and recovery were significantly faster in the group of subjects who received Lysobact® compared to a control group receiving conventional therapy (inhalations and teas). Lysobact® has been shown to be an effective and safe drug in the treatment of acute respiratory diseases. – Kuznecov et al. „Efikasnost preparata Lysobact® u liječenju djece sa dijagnozom akutnog tonzilitisa“ (Efficacy of Lysobact® in the treatment of children diagnosed with acute tonsillitis) The results of a study involving 63 children diagnosed with acute tonsillitis (inflammation of the tonsils) showed that Lysobact® leads to faster clinical recovery and faster normalization of laboratory findings. Lysobact® demonstrates the ability to activate immunobiological forces by reducing the action of antigens on immune cells. Eradication of the pathogen was achieved in all subjects who received Lysobact® compared to the group who received antibiotic therapy, oral antiseptic, and vitamins. – Gorbunov EN., Umanec NP.: „Iskustvo sa primjenom preparata Lysobact® kod peritonzilarnog apscesa“ (Experience with the use of Lysobact® in peritonsillar abscess) Lysobact® has been shown to be very successful in patients with peritonsillar abscess who were included in a control study involving 40 subjects with a diagnosis of peritonsillar abscess. Patients were divided into two groups, one who would receive Lysobact® and antibiotic therapy and the other who would receive only Lysobact® without antibiotics. In both groups, there was an improvement in the clinical picture, and in the group receiving Lysobact® alone, a significantly higher number of children did not show the need for additional antibiotic therapy. Lysobact® has been shown to be a safe drug without side effects. Other references: - Čopjak V., Gavriljak G. The experience of use of Lysobact in treatment of chronic tonsillitis and/or pharyngitis. - Burmak J.G. et al. The experience with use of Lysobact in treatment of acute respiratory virus diseases in children. - Katravenkova N. P. Use of Lysobact in treatment of infective mononucleosis. - Gorbuzov Z.N., Umanec N.P. The experience with use of Lysobact in treatment of paratonsillar abscessus. - Djumin O.V.,Tagunova I.K. The experience with use of Lysobact in the practice work of otorhinolaryngologist. - Gricaj S.O. Efficacy of Lysobact in treatment of acute and chronic oral candidiasis. - Sideljkova L.F. Report on clinical investigation of efficacy of Lysobact and Stomatidin in treatment of parodontal disease. - Kucevljak V.F. The experience with Lysobact in clinic for therapeutic stomatology. - Arifhodžić F. Expert report on the clinical documentation of Lysobact 2000. - Gospodarski I.J., Govda O.V. Use of Lysobact as complex treatment of chronic subatrophic pharyngo-laryngitis in patients with AIDS. - Dedišin L.P., Njanjkovski S.L., Sekretar L.B., Senik L.R., Galapač O.S. Use of Lysobact in prevention of acute respiratory virus infections in children. - Prohorov et al. The experience with use of Lysobact in children with bronchial asthma and chronic sore throat. - Garjuk G.I. Timošenko J.V., Ševčenko A.M., Čuvakov A.M. Efficacy of Lysobact use after tonsillectomy and surgical opening of paratonsillar abscessus. - Lesovaja et al. Clinical and mycrobiological efficacy of Lysobact in treatmetn of diseases of maxilloafacial area. - Parpalej E.A., Novickij A.V. Preventive therapy with Lysobact in treatment of dental caries in children. - Romanenko I.M., Afonjin S.L. Efficacy of treatment with Lysobact in treatment of different diseases of oral cavity in patients with dermatosis of different etiology. - Kosenko K.N., Zaporožec N.N. Clinical and immunological aspects ofuse of Lysobact in treatment of lateral gingivitis in children. - Kucevljak V.F., Babić E.M., Ciganova N.B. Lysobact in pharmacotherapy of inflammatory parodontal diseases. Ova stranica je također dostupna na: Bosnian Albanian Macedonian Serbian Ukrainian Croatian
1.1 1.2 2.1 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1 19.1 20.1 20.2 21.1 22.1 22.2 23.1 24.1 25.1 25.2 26.1 26.2 27.1 28.1 29.1 30.1 31.1 32.1 32.2 33.1 33.2 34.1 34.2 35.1 35.2 35.3 36.1 37.1 37.2 37.3 37.4 38.1 39.1 39.2 40.1 40.2 41.1 41.2 42.1 42.2 43.1 43.2 44.1 44.2 45.1 45.2 46.1 46.2 47.1 47.2 48.1 48.2 49.1 49.2 50.1 50.2 51.1 51.2 51.3 52.1 52.2 53.1 53.2 54.1 54.2 55.1 55.2 56.1 56.2 57.1
Terapijski učinak lizozima u sastavu lijeka Lysobact® na patološka stanja sluznice usne šupljine, kao što su faringitis (upala grla), tonzilitis (upala krajnika), stomatitis (upala sluznice usta), gingivitis (upala desni), stanje nakon vađenja krajnika…, ispitivan je u brojnim kliničkim studijama s primarnim ciljem da se provjeri protivupalno i antimikrobno djelovanje. Klinička ispitivanja su sprovođena u nizu zemalja. – Topić B., Čokorilo N., Arifhodžić F.: “Klinička evaluacija preparata Lyso-6®* u tretmanu aftoznog stimatitisa“ Na Klinici za bolesti usta Stomatološkog fakulteta u Sarajevu, u dvostruko slijepom, placebo kontrolisanom kliničkom ispitivanju dokazana je efikasnost i sigurnost dugotrajne primjene Lysobact® oribleta u pacijenata sa dijagnozom stomatitis aphtosa recurrens. Rezultati ispitivanja koje je uključivalo 60 pacijenata u trajanju od 8 dana su sljedeći: - upala je izliječena petog dana terapije - bol nestaje do petog dana terapije, što je značajno brže u odnosu na kontrolnu placebo-grupu - zarastanje aftoznog oštećenja sluznice je skoro potpuno već petog dana, dok su kod kontrolne placebo-grupe oštećenja sluznice još uvijek prisutna na 40% svoje prvobitne veličine - znaci i simptomi uzrokovani reaktivnom upalom limfnih čvorova znatno su blaži kod pacijenata liječenih oribletama Lysobact® u odnosu na placebo-grupu - Lysobact® efikasno smanjuje jačinu bola i upale, pospješuje zarastanje sluznice na mjestu oštećenja i olakšava simptome upale regionalnih limfnih čvorova - podnošljivost lijeka je bila izvanredna i nisu zapažene bilo kakve toksične ili alergijske pojave * raniji zaštićeni naziv za Lysobact® – Kapidžić A. i sar.: „Otvoreno multicentrično kliničko ispitivanje efikasnosti i sigurnosti primjene lijeka Lysobact® u liječenju i prevenciji postoperativnih komplikacija nakon tonzilektomije“ Na Klinici za ORL KCU u Sarajevu, u otvorenom, paralelnom, kontrolisanom multicentričnom ispitivanju, koje je uključivalo 160 pacijenata starosti od 16 do 40 godina, ispitivana je efikasnost lijeka Lysobact® u poređenju sa standardnom terapijom (analgetik i antibiotik). Rezultati ispitivanja za Lysobact® su pokazali: - značajnu razliku u formiranju fibrinskih naslaga (privremenog bjeličastog pokrova, neophodnog za lakše zarastanje oštećenja) - veće smanjenje osjećaja bola - brže zarastanje postoperativne rane, počevši od drugog postoperatvnog dana - manju potrebu za analgetskom terapijom kod pacijenata liječenih lijekom Lysobact® – Bašić-Đulizarević D., Bajraktarević A., Obradović E: „Evaluacija praktične upotrebe lijeka Lysobact® u periodu 1976 – 2006.“ Meta-analiza devet prospektivnih kliničkih ispitivanja, izvještaji Nacionalnog centra te Centra za lijekove iz Sarajeva, pregled stručne literature te dugogodišnje iskustvo u primjeni lijeka pokazuje da je Lysobact® dokazao odličnu efikasnost u smislu brzog zarastanja oštećenja sluznice usne šupljine te smanjenja jačine upale kao i smanjenje subjektivnog osjećaja bola i osjećaja žarenja sluznice usta. Lysobact® se pokazao kao siguran i efikasan lijek sa antiinflamatornim (protivupalnim) te antibakterijskim, antifungalnim, antivirusnim osobinama uz pozitivan terapijski učinak na bakterije prisutne u zubnom plaku (zubna naslaga). – Zabolotnyj DI., Zaricvaja IS.: „Otvorena studija o efikasnosti i podnošljivosti lijeka Lysobact® u liječenju inflamatornih bolesti farniksa“ Otvoreno, komparativno, paralelno ispitivanje koje je uključivalo 180 pacijenata sa dijagnozom akutnog i hroničnog faringitisa (upala ždrijela/grla) pokazalo je da je Lysobact® efikasniji u smislu bržeg povlačenja simptoma u poređenju sa kombinovanom terapijom antibioticima i otopinom furacilina, koju su ispitanici koristili za ispiranje ždrijela. Lysobact® je pokazao antibakterijski i antiinflamatorni učinak te se preporučuje kod pacijenata sa akutnim i hroničnim faringitisom. – Zabolotnyj DI., Mironjuk BM.: „Otvorena studija s ciljem procjene podnošljivosti preparata Lysobact® u postoperativnom tretmanu nakon tonzilektomije i kriohirurškom zahvatu na palatalnim tonzilama kod djece“ Otvoreno, komparativno, paralelno ispitivanje nakon operativnog zahvata na krajnicima, koje je uključilo 60-oro djece, dječaka i djevojčica starosne dobi od 3 do 7 godina, pokazalo je da se Lysobact® dobro podnosi te da doprinosi bržem zarastanju postoperativne rane. – Andrejčin MA., Borak VP., Išćuk IS., Gospodarska HO. „Efikasnost lijeka Lysobact® u tretmanu grlobolje“ Kontrolno ispitivanje koje je uključivalo 42 pacijenta sa dijagnozom upale grla starosne dobi od 19 do 48 godina, u kojoj su pacijenti podijeljeni u dvije grupe (jedna grupa koja je primala antibiotsku terapiju, antiseptik i vitamin i druga grupa koja je dodatno primala Lysobact®). Kod pacijenata koji su primali i Lysobact® rezultati ispitivanja su pokazali: - brže smanjenje povišene tjelesne temperature - bržu normalizaciju laboratorijskih testova - brže iščezavanje gnojnih nakupina - brže izlječenje pacijenata sa grloboljom Lysobact® se pokazao se kao siguran i dobro podnošljiv lijek. – Burmak i sar. „Kliničko iskustvo sa terapijom preparatom Lysobact® kod djece sa respiratornim virusnim oboljenjem“ Rezultati kontrolnog ispitivanja koje je uključivalo 45-oro djece starosne dobi od 7 do 14 godina sa dijagnozom akutne respiratorne bolesti, od kojih je skoro 20% imalo upalu krajnika, pokazalo je da su poboljšanje simptoma upale i oporavak bili značajno brži u grupi ispitanika koji su primali Lysobact® u poređenju sa kontrolnom grupom koja je primala konvencionalnu terapiju (inhalacije i čajevi). Lysobact® se pokazao kao efikasan i siguran lijek u liječenju akutnih respiratornih bolesti. – Kuznecov i sar. „Efikasnost preparata Lysobact® u liječenju djece sa dijagnozom akutnog tonzilitisa“ Rezultati ispitivanja koje je uključilo 63 djeteta sa dijagnozom akutnog tonzilitisa (upala krajnika) pokazali su da Lysobact® dovodi do bržeg kliničkog oporavka te brže normalizacije laboratorijskih nalaza. Lysobact® pokazuje sposobnost da aktivira imunobiološke snage redukcijom djelovanja antigena na imune ćelije. Eradikacija uzročnika je postignuta kod svih ispitanika koji su primali Lysobact® u poređenju sa grupom koja je primala antibiotsku terapiju, oralni antiseptik i vitamine. – Gorbunov EN., Umanec NP.: „Iskustvo sa primjenom preparata Lysobact® kod peritonzilarnog apscesa“ Primjena lijeka Lysobact® pokazala se veoma uspješnom kod pacijenata sa peritonzilarnim apscesom koji su bili uključeni u kontrolno ispitivanje koje je obuhvatalo 40 ispitanika sa dijagnozom peritonzilarnog apscesa. Pacijenti su bili podijeljeni u dvije grupe, jednu koja će primati Lysobact® i antibiotsku terapiju i drugu koja će primati samo Lysobact® bez antibiotika. U obje grupe je došlo do poboljšanja kliničke slike, a u grupi koja je primala samo Lysobact® značajno veći broj djece nije pokazao potrebu za dodatnom primjenom antibiotske terapije. Lysobact® se pokazao kao siguran lijek bez pojave neželjenih efekata. Ostale reference: - Čopjak V., Gavriljak G. The experience of use of Lysobact in treatment of chronic tonsillitis and/or pharyngitis. - Burmak J.G. et al. The experience with use of Lysobact in treatment of acute respiratory virus diseases in children. - Katravenkova N. Use of Lysobact in treatment of infective mononucleosis. - Gorbuzov Z.N., Umanec N.P. The experience with use of Lysobact in treatment of paratonsillar abscessus. - Djumin O.V.,Tagunova I.K. The experience with use of Lysobact in the practice work of otorhinolaryngologist. - Gricaj S.O. Efficacy of Lysobact in treatment of acute and chronic oral candidiasis. - Sideljkova L.F. Report on clinical investigation of efficacy of Lysobact and Stomatidin in treatment of parodontal disease. - Kucevljak V.F. The experience with Lysobact in clinic for therapeutic stomatology. - Arifhodžić F. Expert report on the clinical documentation of Lysobact 2000. - Gospodarski I.J., Govda O.V. Use of Lysobact as complex treatment of chronic subatrophic pharyngo-laryngitis in patients with AIDS. - Dedišin L.P., Njanjkovski S.L., Sekretar L.B., Senik L.R., Galapač O.S. Use of Lysobact in prevention of acute respiratory virus infections in children. - Prohorov et al. The experience with use of Lysobact in children with bronchial asthma and chronic sore throat. - Garjuk G.I. Timošenko J.V., Ševčenko A.M., Čuvakov A.M. Efficacy of Lysobact use after tonsillectomy and surgical opening of paratonsillar abscessus. - Lesovaja et al. Clinical and mycrobiological efficacy of Lysobact in treatmetn of diseases of maxilloafacial area. - Parpalej E.A., Novickij A.V. Preventive therapy with Lysobact in treatment of dental caries in children. - Romanenko I.M., Afonjin S.L. Efficacy of treatment with Lysobact in treatment of different diseases of oral cavity in patients with dermatosis of different etiology. - Kosenko K.N., Zaporožec N.N. Clinical and immunological aspects ofuse of Lysobact in treatment of lateral gingivitis in children. - Kucevljak V.F., Babić E.M., Ciganova N.B. Lysobact in pharmacotherapy of inflammatory parodontal diseases. Ova stranica je također dostupna na: Albanski Makedonski Srpski Ukrajinski Engleski Hrvatski